Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates

Journal of Medicinal Chemistry

Volumn 51, Issue 4, 2008, Pages 713-716

  Fang, Lei ^a,b   Appenroth, Dorothea ^a   Decker, Michael ^a,c   Kiehntopf, Michael ^a   Roegler, Carolin ^a   Deufel, Thomas ^a   Fleck, Christian ^a   Peng, Sixun ^b   Zhang, Yihua ^b   Lehmann, Jochen ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACRINE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; LIVER PROTECTION; LIVER TOXICITY; NONHUMAN; PULMONARY ARTERY; VASODILATATION;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; LIVER; MUSCLE RELAXATION; NITRIC OXIDE DONORS; PULMONARY ARTERY; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; TACRINE;

EID: 39749166281     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701491k     Document Type: Article

References (30)

1. Francotte, P; Graindorgea, E.; Boveriea, S.; de Tullioa, P.; Pirottea, B. New Trends in the Design of Drugs against Alzheimer's Disease. Curr. Med. Chem 2004, 11, 1757-1778.
2. Scarpini, E.; Scheltens, P.; Feldman, H. Treatment of Alzheimer's Disease: Current Status and New Perspectives. Neurology 2003, 2, 539-547.
3. Knapp, M. J.; Knopman, D. S.; Soloman, P. R.; Pendlebury, W. W.; Davis, C. S.; Gracon, S. I. A 30-week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease. J. Am. Med. Assoc. 1994, 271, 985-991.
4. Crismon, M. L. Tacrine: First Drug Approved for Alzheimer's Disease. Ann. Pharmacother. 1994, 28, 744-751.
5. Watkins, P. B.; Zimmerman, H. J.; Knapp, M. J.; Gracon, S. I.; Lewis, K. W. Hepatotoxic Effects of Tacrine Administration In Patients with Alzheimer's Disease. J. Am. Med. Assoc. 1994, 271, 992-998.
6. Ames, D. J.; Bhathal, P. S.; Davies, B. M.; Fraser, J. R. E.; Gibson, P. R.; Roberts, S. Heterogenecity of Adverse Hepatic Reactions to Tetrahydroaminoacridine. N. Z. J. Med. 1990, 20, 193-195.
7. Decker, M. Recent Advances in the Development of Hybrid Molecules/Designed Multiple Compounds with Antiamnesic Properties. Mini-Rev. Med. Chem. 2007, 7, 221-229.
8. Youdim, M. B. H.; Buccafusco, J. J. Multi-Functional Drugs for Various CNS Targets in the Treatment of Neurodegenerative Disorders. Trends Pharmacol. Sci. 2005, 26, 27-35.
9. (a) Hu, M. K.; Wu, L. J.; Hsiao, G.; Yen, M. H. Homodimeric Tacrine Congeners as Acetylcholinesterase Inhibitors. J. Med. Chem. 2002, 45, 2277-2282.
10. (b) Carlier, P. R.; Chow, E. S.-H.; Han, Y.; Liu, J.; Yazal, J. E.; Pang, Y.-P. Heterodimeric Tacrine-Based Acetylcholinesterase Inhibitors: Investigating Ligand-Peripheral Site Interactions. J. Med. Chem. 1999, 42, 4225-4231.
11. (c) Carlier, P. R.; Du, D.-M.; Han, Y.-F.; Liu, J.; Pang, Y.-P. Potent Easily Synthesized Huperzine A-Tacrine Hybrid Acetylcholinesterase Inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 2335-2338.
12. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational Approach To Discover Multipotent Anti-Alzheimer Drugs. J. Med. Chem. 2005, 48, 360-363.
13. Marco-Contelles, J.; León, R.; de los Ríos, C.; Guglietta, A.; Terencio, J.; López, M. G.; García, A. G.; Villarroya, M. Novel Multipotent Tacrine-Dihydropyridine Hybrids with Improved Acetylcholinesterase Inhibitory and Neuroprotective Activities as Potential Drugs for the Treatment of Alzheimer's Disease. J. Med. Chem. 2006, 49, 7607-7610.
14. Perissutti, E.; Fiorino, F.; Severino, B.; Frecentese, F.; Massarelli, P.; Nencini, C.; Santagada, V.; Caliendo, G. Synthesis of 6β-D- Glucosyl and 6-Nitroxy (-)-Galanthamine Derivatives as Acetylcholinesterase Inhibitors. Pharmazie 2007, 62, 403-405.
15. Megson, I. L.; Webb, D. J. Nitric Oxide Donor Drugs: Current Status and Future Trends. Expert Opin. Invest. Drugs 2002, 11, 587-601.
16. Thatcher, G. R. J.; Bennett, B. M.; Reynolds, J. N. Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimer's Disease. Curr. Alzheimer Res. 2005, 2, 171-182.
17. Bartolini, M.; Bertucci, C.; Cavrini, V.; Andrisano, V. β-Amyloid Aggregation Induced by Human Acetylcholinesterase: Inhibition Studies. Biochem. Pharmacol. 2003, 65, 407-416.
18. Gemma, S.; Gabellieri, E.; Huleatt, P.; Fattorusso, C.; Borriello, M.; Catalanotti, B.; Butini, S.; De Angelis, M.; Novellino, E.; Nacci, V.; Belinskaya, T.; Saxena, A.; Campiani, G. Discovery of Huperzine A-Tacrine Hybrids as Potent Inhibitors of Human Cholinesterases Targeting Their Midgorge Recognition Sites. J. Med. Chem. 2006, 49, 3421-3425.
19. Carlier, P. R.; Han, Y. F.; Chow, E. S.-H.; Li, C. P.-L.; Wang, H.; Lieu, T. X.; Wong, H. S.; Pang, Y.-P. Evaluation of Short-Tether Bis-THA AChE Inhibitors. A Further Test of the Dual Binding Site Hypothesis. Bioorg. Med. Chem. 1999, 7, 351-357.
20. Velázquez, C.; Rao, P. N. P.; Knaus, E. E. Novel Nonsteroidal Anti-Inflammatory Drugs Possessing a Nitric Oxide Donor Diazen-1-ium-1,2-diolate Moiety: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies. J. Med. Chem. 2005, 48, 4061-4067.
21. Decker, M.; Koenig, A.; Glusa, E.; Lehmann, J. Synthesis and Vasorelaxant Properties of Hybrid Molecules Out of NO-Donors and the Beta-Receptor Blocking Drug Propranolol. Bioorg. Med. Chem. Lett. 2004, 14, 4995-4997.
22. Decker, M. Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from the Alkaloids Dehydroevodiamine and Rutaecarpine. Eur. J. Med. Chem. 2005, 40, 305-313.
23. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity. Biochem. Pharmacol. 1961, 7, 88-95.
24. Giacobini, E. Cognitive Enhancing Drugs; Birkhäuser Verlag: Basel, Boston, Berlin, 2004; pp 11-36.
25. Saxena, A.; Redman, A. M. G.; Jiang, X.; Lockridge, O.; Doctor, B. P. Differences in Active Site Gorge Dimension of Cholinesterases Revealed by Binding of Inhibitors to Human Butyrylcholinesterase. Biochemistry 1997, 36, 14642-14651.
26. Duncan, A. J.; Heales, S. J. R. Nitric Oxide and Neurological Disorders. Mol. Aspects Med. 2005, 26, 67-96.
27. Gracon, S. I.; Knapp, M. J.; Berghoff, W. G.; Pierce, M.; de Jong, R.; Lobbestael, S. J.; Symons, J.; Dombey, S. L.; Luscombe, F. A.; Kraemer, D. Safety of Tacrine: Clinical Trials, Treatment IND, and Postmarketing Experience. Alzheimer Dis. Assoc. Disord. 1998, 12, 93-101.
28. Liu, J.; Waalkes, M. P. Nitric Oxide and Chemically Induced Hepatotoxicity: Beneficial Effects of the Liver-Selective Nitric Oxide Donor, V-PYRRO/NO. Toxicology 2005, 208, 289-297.
29. 2-vinyl 1-(Pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO), Protects against Cadmium-Induced Hepatotoxicity in Mice. J. Pharmacol. Exp. Ther. 2004, 310, 18-24.
30. Futter, L. E.; al-Swayeh, O. A.; Moore, P. K. A Comparison of the Effect of Nitroparacetamol and Paracetamol on Liver Injury. Br. J. Pharmacol. 2001, 132, 10-12.